Skip to main
PODD

Insulet (PODD) Stock Forecast & Price Target

Insulet (PODD) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 44%
Buy 50%
Hold 0%
Sell 6%
Strong Sell 0%

Bulls say

Insulet has demonstrated significant growth momentum, achieving record new customer starts in the fourth quarter of 2025, with notable year-over-year and sequential acceleration in both the U.S. and international markets. The company reported revenues of $784 million for Q4, marking a 31% increase year-over-year, driven by strong volume growth, enhanced manufacturing productivity, and favorable pricing dynamics from existing customer transitions. Additionally, Insulet's proactive investment strategy is evidenced by a capital expenditure increase to $135 million, aimed at expanding manufacturing capacity and developing future facilities, reinforcing its commitment to meet rising demand.

Bears say

Insulet's stock faces a negative outlook primarily due to sustained poor sentiment within the therapeutic sector, particularly as competitors trade at historically low levels, reflecting concerns over accelerated GLP-1 adoption impacting demand. Additionally, the company's growth estimates for the US Omnipod have shown modest projections of 20-22%, while faced with a significant decline of approximately 50% in the drug delivery segment, indicating vulnerability in core business areas. The overarching risks, including heightened competition in the pump market and potential delays in pipeline product approvals, further contribute to the negative sentiment surrounding Insulet’s financial projections.

Insulet (PODD) has been analyzed by 18 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 6% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insulet and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insulet (PODD) Forecast

Analysts have given Insulet (PODD) a Buy based on their latest research and market trends.

According to 18 analysts, Insulet (PODD) has a Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $354.61, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $354.61, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insulet (PODD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.